50th anniversary of the discovery of ibuprofen: an interview with Dr Stewart Adams

References

• Ligon BL. Penicillin: Its discovery and early development. Semin Pediatr Infect Dis 2004; 15: 52–57
   PubMedGoogle Scholar
• Adams SS. Ibuprofen, the propionics and NSAIDs: Personal reflections over four decades. Inflammopharmacology 1999; 7: 191–197
   PubMedGoogle Scholar
• Adams SS. The propionic acids: A personal perspective. J Clin Pharmacol 1992; 32: 317–323
   PubMed Web of Science ®Google Scholar
• Harris SC, Fosdick LS. Theoretical considerations of the mechanisms of antipyretic analgesia. NWU Bull 1952; 53: 6–9
   Google Scholar
• CORTISONE and aspirin. Br Med J 1955;2:725-726
   Google Scholar
• Mottram PL. Past, present and future drug treatment for rheumatoid arthritis and systemic lupus erythematosus. Immunol Cell Biol 2003; 81: 350–353
   PubMed Web of Science ®Google Scholar
• Adams SS, Cobb R. A possible basis for the anti-inflammatory activity of salicylates and other non-hormonal anti-rheumatic drugs. Nature 1958; 181: 773–774
   PubMed Web of Science ®Google Scholar
• Adams SS. Some reflections on ibuprofen. J R Soc Med 2007; 100 Suppl 48: 1
   PubMed Web of Science ®Google Scholar
• Wilhelmi G. [Antiphlogistic effect of pyrazols, especially of irgapyrin, in peroral and parenteral administration]. Schweiz Med Wochenschr 1950; 80: 936–942
   PubMedGoogle Scholar
• Winder CV, Wax J, Burr V, Been M, Rosiere CE. A study of pharmacological influences on ultraviolet erythema in guinea pigs. Arch Int Pharmacodyn Ther 1958; 116: 261–293
   PubMedGoogle Scholar
• Adams SS, The testing of non-hormonal anti-rheumatic compounds. Research Department Report. No. 848: Boots Pure Drug Co. Ltd. 1956.
   Google Scholar
• Adams SS, Bough RG, Cliffe EE, Dickinson W, Lessel B, McCullough KF, Mills RF, Nicholson JS, Williams GA. Some aspects of the pharmacology, metabolism, and toxicology of ibuprofen. I. Pharmacology and metabolism. Rheumatol Phys Med 1970; 10: Suppl 10:9–26
   Google Scholar
• Adams SS, Cliffe EE, Lessel B, Nicholson JS. Some biological properties of 2-(4-isoburylphenyl)-propionic acid. J Pharm Sci 1967; 56: 1686
   PubMed Web of Science ®Google Scholar
• Mills RF, Adams SS, Cliffe EE, Dickinson W, Nicholson JS. The metabolism of ibuprofen. Xenobiotica 1973; 3: 589–598
   PubMed Web of Science ®Google Scholar
• Adams SS, Bough RG, Cliffe EE, Lessel B, Mills RF. Absorption, distribution and toxicity of ibuprofen. Toxicol Appl Pharmacol 1969; 15: 310–330
   PubMed Web of Science ®Google Scholar
• Adams SS, McCullough KF, Nicholson JS. The pharmacological properties of ibuprofen, an anti-inflammatory, analgesic and antipyretic agent. Arch Int Pharmacodyn Ther 1969; 178: 115–129
   PubMedGoogle Scholar
• Moore N. Ibuprofen: A journey from prescription to over-the-counter use. J R Soc Med 2007; 100 Suppl 48: 2–6
   PubMed Web of Science ®Google Scholar
• Mustard JF, Packham MA, Kinlough-Rathbone RL. Non-steroidal anti-inflammatory agents and coronary heart disease. Acta Med Scand Suppl 1980; 642: 180–190
   PubMedGoogle Scholar
• Baele G, De Weerdt GA, Barbier F. Preliminary results of platelet aggregation before and after administration of ibuprofen. Rheumatol Phys Med 1970; 10(Suppl 10)108–111
   Google Scholar
• Ikeda Y. The effect of ibuprofen on platelet function in vivo. Keio J Med 1977; 26: 213–222
   PubMedGoogle Scholar
• McIntyre BA, Philp RB, Inwood MJ. Effect of ibuprofen on platelet function in normal subjects and hemophiliac patients. Clin Pharmacol Ther 1978; 24: 616–621
   PubMed Web of Science ®Google Scholar
• Lefer AM, Polansky EW. Beneficial effects of ibuprofen in acute myocardial ischemia. Cardiology 1979; 64: 265–279
   PubMed Web of Science ®Google Scholar
• Lefer AM, Crossley K. Mechanisms of the optimal protective effects of ibuprofen in acute myocardial ischemia. Adv Shock Res 1980; 3: 133–141
   PubMedGoogle Scholar
• Hong Y, Gengo FM, Rainka MM, Bates VE, Mager DE. Population pharmacodynamic modelling of aspirin- and Ibuprofen-induced inhibition of platelet aggregation in healthy subjects. Clin Pharmacokinet 2008; 47: 129–137
   PubMed Web of Science ®Google Scholar
• Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: An observational cohort study. Lancet 2002; 359: 118–123
   PubMed Web of Science ®Google Scholar
• Rao GH, Johnson GG, Reddy KR, White JG. Ibuprofen protects platelet cyclooxygenase from irreversible inhibition by aspirin. Arteriosclerosis 1983; 3: 383–388
   PubMedGoogle Scholar
• Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, Vyas SN, FitzGerald GA. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809–1817
   PubMed Web of Science ®Google Scholar
• Gengo FM, Rubin L, Robson M, Rainka M, Gengo MF, Mager DE, Bates V. Effects of ibuprofen on the magnitude and duration of aspirin's inhibition of platelet aggregation: Clinical consequences in stroke prophylaxis. J Clin Pharmacol 2008; 48: 117–122
   PubMed Web of Science ®Google Scholar
• Kurth T, Glynn RJ, Walker AM, Chan KA, Buring JE, Hennekens CH, Gaziano JM. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 2003; 108: 1191–1195
   PubMed Web of Science ®Google Scholar
• Schjerning Olsen AM, Fosbol EL, Lindhardsen J, Folke F, Charlot M, Selmer C, Lamberts M, Bjerring Olesen J, Kober L, Hansen PR, Torp-Pedersen C, Gislason GH. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: A nationwide cohort study. Circulation 2011; 123: 2226–2235
   PubMed Web of Science ®Google Scholar
• Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, Egger M, Juni P. Cardiovascular safety of non-steroidal anti-inflammatory drugs: Network meta-analysis. BMJ 2011; 342: c7086
   PubMed Web of Science ®Google Scholar
• Ohlsson A, Walia R, Shah SS, Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2010:CD003481
   Google Scholar
• Mahony L, Carnero V, Brett C, Heymann MA, Clyman RI. Prophylactic indomethacin therapy for patent ductus arteriosus in very-low-birth-weight infants. N Engl J Med 1982; 306: 506–510
   PubMed Web of Science ®Google Scholar
• Gagne JJ, Power MC. Anti-inflammatory drugs and risk of Parkinson disease: A meta-analysis. Neurology 2010; 74: 995–1002
   PubMed Web of Science ®Google Scholar
• Samii A, Etminan M, Wiens MO, Jafari S. NSAID use and the risk of Parkinson's disease: Systematic review and meta-analysis of observational studies. Drugs Aging 2009; 26: 769–779
   PubMed Web of Science ®Google Scholar
• Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, Ascherio A. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol 2005; 58: 963–967
   PubMed Web of Science ®Google Scholar
• Gao X, Chen H, Schwarzschild MA, Ascherio A. Use of ibuprofen and risk of Parkinson disease. Neurology 2011; 76: 863–869
   PubMed Web of Science ®Google Scholar
• Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231: 232–235
   PubMedGoogle Scholar
• Adams SS. Non-steroidal anti-inflammatory drugs, plasma half-lives, and adverse reactions. Lancet 1987; 2: 1204–1205
   PubMed Web of Science ®Google Scholar
• Adams SS. NSAIDs, plasma half-lives, and adverse reactions. Lancet 1988; 1: 653–654
   PubMedGoogle Scholar
• Rainsford KD. Ibuprofen: Pharmacology, efficacy and safety. Inflammopharmacology 2009; 17: 275–342
   PubMedGoogle Scholar